GMAB
HealthcareGenmab A/S · Biotechnology · $17B
What is Genmab A/S?
Genmab A/S is a Danish biotechnology company focused on developing differentiated antibody therapeutics for cancer and other serious diseases. Headquartered in Copenhagen, it has built a broad commercial and clinical portfolio through strategic partnerships with major pharmaceutical companies.
Genmab generates revenue primarily through royalties, milestone payments, and collaboration agreements tied to its antibody products. Its flagship asset, daratumumab, is marketed as DARZALEX for multiple myeloma and related blood cancers. The company co-develops and licenses additional therapies — including treatments for cervical cancer, thyroid eye disease, and chronic lymphocytic leukemia — through partnerships with global pharmaceutical leaders, allowing it to share development costs while retaining meaningful economic participation.
Genmab was founded in 2009 and is headquartered in Copenhagen, Denmark.
- DARZALEX (daratumumab) for multiple myeloma and blood cancers
- Epcoritamab for relapsed or refractory large B-cell lymphoma
- Tisotumab vedotin for cervical and solid tumors
- Amivantamab for gastric, esophageal, and lung cancers
- Ofatumumab for chronic lymphocytic leukemia and multiple sclerosis
Is GMAB a Good Stock to Buy?
UQS Score rates GMAB as Good overall, reflecting a balanced profile across its five analytical pillars.
Genmab's Quality pillar stands out as Strong, consistent with a company that has established commercial products generating durable royalty streams. The Risk pillar also rates Good, suggesting the business carries a manageable risk profile relative to typical biotech peers — a function of its diversified partnership structure and multiple revenue-contributing assets.
The Growth pillar rates Weak, indicating that near-term expansion expectations are more muted compared to earlier-stage peers, while the Moat pillar sits at Neutral, reflecting ongoing competitive pressure in oncology.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GMAB pay dividends?
No — Genmab A/S does not currently pay a dividend.
Genmab does not currently pay a dividend. For a clinical-stage and royalty-driven biotech, this is typical — capital is directed toward advancing the pipeline, funding clinical trials, and supporting partnership obligations. Investors in GMAB are generally seeking long-term value creation through pipeline progress rather than current income.
When does GMAB report earnings?
Genmab reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Results in recent periods have reflected the royalty-heavy nature of Genmab's business model, with revenue closely tied to DARZALEX's commercial performance and milestone receipts from collaboration partners. Pipeline advancement and partnership updates tend to be key focal points for investors each quarter.
For the most recent quarter's results and guidance, visit Genmab's official investor relations page.
GMAB Price History
-33.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Genmab A/S?
Based on Genmab A/S's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GMAB Long-term Outlook
Genmab's fundamental outlook is shaped by the interplay between its Good Risk profile and Weak Growth pillar. The business benefits from a relatively stable royalty base anchored by established products, but near-term growth acceleration appears constrained. Longer-term trajectory will depend on late-stage pipeline readouts and the commercial uptake of newer assets like epcoritamab and tisotumab vedotin.
Growth drivers
- Continued global expansion of DARZALEX across multiple myeloma indications
- Commercial ramp of epcoritamab and tisotumab vedotin in oncology
- Milestone and royalty income from a broad network of pharmaceutical partnerships
Key risks
- Pipeline clinical setbacks or regulatory delays for late-stage assets
- Dependence on partner execution for commercial success of co-developed therapies
- Competitive pressure in oncology from emerging antibody and cell therapy platforms
GMAB vs Peers
Genmab operates in a competitive oncology and rare-disease biotech landscape alongside several focused peers.
Incyte focuses on small-molecule and biologic therapies for oncology and inflammatory diseases, with a more diversified therapeutic area mix than Genmab's antibody-centric approach.
Summit is a clinical-stage company advancing targeted oncology treatments, operating at an earlier commercial stage than Genmab with a narrower current product portfolio.
Ascendis, also a Danish biotech, applies its TransCon technology platform across endocrinology and rare diseases, differentiating it from Genmab's oncology-focused antibody strategy.
Frequently Asked Questions
What does Genmab do?
Genmab is a biotechnology company that develops antibody-based therapies, primarily targeting cancer. It earns revenue through royalties and milestone payments from partners who commercialize its drugs, including the widely used multiple myeloma treatment DARZALEX. The company also has a broad clinical pipeline spanning blood cancers, solid tumors, and select non-oncology diseases.
Does GMAB pay dividends?
Genmab does not pay a dividend. The company reinvests available capital into its clinical pipeline and partnership activities rather than returning cash to shareholders through distributions. Investors focused on income may find GMAB less suitable than dividend-paying healthcare peers.
When does GMAB report earnings?
Genmab reports financial results on a quarterly basis, in line with standard practice for US-listed companies. For precise dates and the latest quarterly disclosures, check Genmab's investor relations page directly, as our data source does not cover forward earnings dates.
Is GMAB a good stock to buy?
UQS Score rates GMAB as Good overall. The Quality and Risk pillars are among the stronger elements of its profile, while Growth rates Weak. Whether GMAB fits a portfolio depends on individual goals — the full pillar breakdown available to Pro members provides a more complete picture.
Is GMAB overvalued?
The UQS Valuation pillar for GMAB rates Good, suggesting the stock does not appear significantly stretched relative to its fundamental profile. Valuation in biotech is inherently complex given pipeline optionality — Pro members can view the detailed valuation metrics behind this rating.
How does GMAB compare to its competitors?
Among peers like Incyte, Summit Therapeutics, and Ascendis Pharma, Genmab stands out for its established royalty revenue base and diversified antibody pipeline. Competitors vary in therapeutic focus and commercial maturity. The UQS platform scores each ticker independently, allowing side-by-side comparison of pillar ratings.
What is GMAB's market cap bracket?
Genmab is classified as a large-cap stock. This places it among the more established publicly traded biotechnology companies globally, with a scale that supports ongoing investment in clinical development and partnership infrastructure.
Who founded Genmab?
Genmab was founded in 1999 by Jan van de Winkel and Lisa Drakeman, with its origins rooted in antibody technology research. The company has since grown into one of Europe's leading antibody-focused biotechs, headquartered in Copenhagen, Denmark.
Is GMAB a long-term quality indicator?
From a long-term quality perspective, Genmab's Strong Quality pillar and Good Risk rating suggest a business with durable fundamentals relative to many biotech peers. However, the Weak Growth pillar indicates investors should weigh pipeline execution risk carefully. Pro members can access the full multi-pillar view to assess long-term positioning.
What is the main competitive advantage of Genmab?
Genmab's primary edge lies in its proprietary antibody technology platforms — including DuoBody and HexaBody — which enable the creation of differentiated bispecific and enhanced antibody therapies. These platforms underpin its partnership appeal and have produced multiple commercial-stage products generating ongoing royalty income.
What sector does GMAB belong to?
Genmab operates in the Healthcare sector, specifically within biotechnology. Its focus on antibody therapeutics for oncology and rare diseases places it among specialty biotech companies rather than diversified pharmaceutical firms. You can explore more [healthcare sector stocks](/sector/healthcare) on the UQS platform.
Is GMAB a growth stock or value stock?
Based on UQS pillar ratings, GMAB presents a mixed profile — the Growth pillar rates Weak while the Valuation pillar rates Good. This positions it closer to a quality-and-value profile than a high-growth biotech, though pipeline catalysts could shift that balance over time.
Unlock Full GMAB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare GMAB side-by-side with biotech peers
- ✓Track pipeline and partnership risk indicators
- ✓Get the complete analyst-grade quality breakdown
- ✓Screen top healthcare stocks by UQS pillar strength
Pro Analysis
GMAB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 65.2 | 88.0 | 44.0 | 35.9 | 92.3 | 74.3 | -0.2 |
| May 17, 2026 | 65.4 | 88.4 | 44.0 | 35.9 | 92.3 | 75.4 | 0.0 |
| May 13, 2026 | 65.4 | 88.2 | 44.0 | 35.9 | 92.3 | 75.4 | +0.3 |
| May 12, 2026 | 65.1 | 88.6 | 44.0 | 35.3 | 92.3 | 73.7 | -1.6 |
| May 9, 2026 | 66.7 | 95.2 | 44.0 | 48.0 | 68.0 | 80.9 | +4.6 |
| May 7, 2026 | 62.1 | 90.6 | 44.0 | 36.0 | 68.0 | 73.5 | -0.3 |
| May 3, 2026 | 62.4 | 90.6 | 44.0 | 36.0 | 68.0 | 75.7 | +0.1 |
| Apr 26, 2026 | 62.3 | 90.6 | 44.0 | 36.0 | 68.0 | 75.1 | +0.4 |
| Apr 24, 2026 | 61.9 | 90.6 | 44.0 | 36.0 | 68.0 | 72.5 | -0.8 |
| Apr 20, 2026 | 62.7 | 90.6 | 44.0 | 37.3 | 68.0 | 76.1 | -0.8 |
GMAB — Pillar Breakdown
Quality
— 88.1/100 (25%)Genmab A/S demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.0/100 (20%)Genmab A/S shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 66.9/100 (15%)Genmab A/S maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 74.7/100 (15%)Genmab A/S trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 44/100 (25%)Genmab A/S possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GMAB.
Score Composition
Financial Data
More Stock Analysis
How is the GMAB UQS Score Calculated?
The UQS (Unified Quality Score) for Genmab A/S is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Genmab A/S's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Genmab A/S is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.